VivoSim Labs, INC.
VIVS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001497253
In the last 90 days, VivoSim Labs, INC. insiders filed 1 open-market purchase and 0 sales; 25 institutions reported holding it in 13F filings for Q2 2026, worth $109.7K in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $2.30M
- Insider buysLast 90 days, $2.80K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 25
- 13F valueReported value at the end of Q2 2026
- $109.7K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2026
- $131.0K
- −9.0% year over year
- Net income, FY2026
- -$13.8M
- No comparable prior period
- Free cash flow, FY2026
- -$10.8M
- No comparable prior period
- Revenue, Q1 FY2027
- $18.0K
- −51.4% year over year
Revenue flow, FY2026
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2026: $13.8M (10567.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 649.6K
- Shares sold short
- Change
- +51.1K
- +8.6% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding VIVS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding VIVS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by VivoSim Labs, INC. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 (view filing)4:01 PM ET | Aug 31 | 1 day | Lialin Tony SergeChief Commercial Officer | PPurchase | +10.0K | $0.2804 | +$2.80K | New position10.0K after | |
| Nov 19, 2025 (view filing) | Nov 17 | 2 days | Gobel DavidDirector | SSale | +3.27K | $2.24 | +$7.32K | New position0 after | |
| Nov 17, 2023 (view filing) | Nov 15 | 2 days | Gobel DavidDirector | SSale | −19.6K | $1.62 | −$31.8K | −100.0%0 after | |
| Aug 19, 2021 (view filing) | Aug 17 | 2 days | Cohen Douglas JayDirector | PPurchase | +8.75K | $6.72 | +$58.8K | +700.0%10.0K after | |
| Aug 19, 2021 (view filing) | Aug 17 | 2 days | Cohen Douglas JayDirector | PPurchase | +2.00K | $6.73 | +$13.5K | New position1.00K after | 2 lots |
Top 10 13F holders, Q2 2026
See all 25 holdersThe largest institutional positions in VivoSim Labs, INC. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 25,976 | $27.8K | 0.00% | −10,874−29.5% | Reduced |
| Renaissance Technologies LLC | 18,500 | $19.8K | 0.00% | +18,500 | New |
| HRT Financial LP | 18,319 | $19.0K | 0.00% | +18,319 | New |
| Vanguard Capital Management LLC | 15,371 | $16.4K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 11,817 | $12.6K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 7,003 | $7.49K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 5,249 | $5.62K | 0.00% | +2,941+127.4% | Added |
| SBI Securities Co., Ltd. | 221 | $236 | 0.00% | 00.0% | Unchanged |
| Larson Financial Group LLC | 166 | $178 | 0.00% | 00.0% | Unchanged |
| Albion Financial Group | 159 | $171 | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of VIVS
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of VivoSim Labs, INC..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Esousa Group Holdings LLC | 13G/A | 9.90%319.4K shares | 0.00 ppfrom 9.90% | Apr 6, 20262 filings | Aug 17, 2026 | SEC |